CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory
Kidani Y, Nogami W, Yasumizu Y, Kawashima A, Tanaka A, Sonoda Y, Tona Y, Nashiki K, Matsumoto R, Hagiwara M, Osaki M, Dohi K, Kanazawa T, Ueyama A, Yoshikawa M, Yoshida T, Matsumoto M, Hojo K, Shinonome S, Yoshida H, Hirata M, Haruna M, Nakamura Y, Motooka D, Okuzaki D, Sugiyama Y, Kinoshita M, Okuno T, Kato T, Hatano K, Uemura M, Imamura R, Yokoi K, Tanemura A, Shintani Y, Kimura T, Nonomura N, Wada H, Mori M, Doki Y, Ohkura N, Sakaguchi S. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2114282119. PMID: 35140181, PMCID: PMC8851483, DOI: 10.1073/pnas.2114282119.Peer-Reviewed Original ResearchConceptsTumor TregsTumor immunityMAb treatmentTumor tissuesT cellsLong-lasting memoryCD4<sup>+</sup> regulatory T cellsPD-1 immune checkpoint blockadeCures of established tumorsInduce severe autoimmune diseaseSuppress antitumor immune responsesImmune responseT cell receptor clonotypesImmune checkpoint blockadeSystemic Treg depletionAntitumor immune responseConventional T cellsRegulatory T cellsTumor-associated antigensChemokine receptor CCR8Several autoimmune diseasesSecondary immune responseTreg depletionCheckpoint blockadePD-1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply